Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localization accuracy of FAPI-PET/fluorescence were compared and analyzed.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 70 years old; * Have complete clinical and imaging data; * Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer; * Able to retain sufficient tumor tissue for testing and research; * Sign informed consent. Exclusion Criteria: * Previously combined with other malignant tumors or received other anti-tumor treatments; * Failure to collect sufficient tumor tissue for testing and research; * The duration of neoadjuvant therapy is less than 3 cycles; * The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing; * Lack of clinical and imaging data; * There are situations where other researchers consider it inappropriate to participate in this study